Pallone on New Alzheimer’s Disease Drug Lecanemab

Energy and Commerce Committee incoming Ranking Member Frank Pallone, Jr. (D-NJ) released the following statement today after the Food and Drug Administration (FDA) granted accelerated approval to Eisai and Biogen's new Alzheimer's Disease drug lecanemab:

"Today's approval is an important day in the ongoing search for new cures and treatments to address devastating diseases like Alzheimer's. I'm hopeful lecanemab will live up to its promise of slowing the progression of Alzheimer's disease for patients and their loved ones. I'm also hopeful Eisai and Biogen have learned from past mistakes and will price lecanemab fairly to ensure patients have equitable access to this drug. I'll be keeping a very close eye on their pricing decisions in the days ahead because treatments and cures only work when patients can afford them."

Last month, Pallone and then House Oversight and Reform Chairwoman Carolyn Maloney (D-NY) released a report following an 18-month investigation into FDA's regulatory review and approval process and Biogen's pricing of its first Alzheimer's Disease medication, Aduhelm.

###